Compare SLNG & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | ENTX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0M | 142.0M |
| IPO Year | N/A | 2018 |
| Metric | SLNG | ENTX |
|---|---|---|
| Price | $4.47 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | $10.00 |
| AVG Volume (30 Days) | 6.3K | ★ 140.5K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $72,270,000.00 | $124,000.00 |
| Revenue This Year | $7.02 | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $83.98 | ★ N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $3.29 | $1.50 |
| 52 Week High | $8.28 | $3.22 |
| Indicator | SLNG | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 39.07 |
| Support Level | $4.15 | $1.53 |
| Resistance Level | $4.38 | $2.04 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 34.58 | 40.58 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.